| HOME >> BIOLOGY >> TECHNOLOGY |
Progress of Ongoing Programmes Confirmed
REINACH and BASEL, Switzerland, November 2 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presents two clinical posters on its late-stage investigational antibiotic iclaprim at the 9th annual congress for Clinical Pharmacology (Verbund Klinische Pharmakologie - VKliPha) which takes place 1-3 November in Kiel, Germany. The posters presented at the conference further expand the substantial volume of data on iclaprim that is already available. At two recent conferences in the United States, Arpida has presented a total of 24 posters on iclaprim.
Poster F-1 discusses results of Phase I studies with intravenous iclaprim in healthy volunteers. In the studies, iclaprim showed linear, predictable and gender-independent pharmacokinetic characteristics in a clinically relevant dose range. Moreover, results showed iclaprim to be safe and well-tolerated in the studies.
Poster F-25 examines the influence of ketoconazole on the pharmacokinetics and safety of intravenous iclaprim. Ketoconazole did not affect the pharmacokinetics of iclaprim. Ketoconazole is a synthetic antifungal drug used to prevent and treat skin and fungal infections, especially in immunocompromised patients. In drug-drug interaction studies, it is often used as a reference compound due to its potent inhibition of the cytochrome P450 3A4 system
Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The
data presented in Kiel highlight several aspects of iclaprim's attractive
profile. In these Phase I studies iclaprim's pharmacokinetics were shown to
be predictable and unaffected by ketaconazole. Moreover, the good safety
profile was confirmed. As at the previous ICAAC and IDSA conferences, we've
encountered a lively interest in iclaprim among the congress attendees in
Kiel. This again reinforces the view that there is an urgent need for new
pathogen-focused antibiotics to address some of the most threatening
multi
'/>"/>
| SOURCE Arpida Ltd. Copyright©2007 PR Newswire. All rights reserved |